Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC).
In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. DB-07 is an open label, phase 1b/2 study investigating T-Dxd monotherapy vs. T-Dxd + pertuzumab as first line treatment in mBC. The primary objective of the dose expansion part of the trial was to assess safety and tolerability.
The abstract entitled ‘Dose-expansion study of Trastuzumab Deruxtecan as monotherapy or combined with Pertuzumab in patients With metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer in DESTINY-Breast07 (DB-07)’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.
- What is known about the efficacy and safety of trastuzumab deruxtecan as monotherapy in patients with HER2+ unresectable/metastatic breast cancer? (0:20)
- What is the rationale for combining trastuzumab deruxtecan with other treatments? (1:19)
- What were the aims, design and preliminary results from the DESTINY-Breast07 study? (2:13)
- What other trastuzumab deruxtecan combinations are being investigated? (3:39)
Disclosures: Erika Hamilton is a consultant for Arcus, AstraZeneca, Daiichi Sankyo, Ellipses Pharma, Greenwich LifeSciences, iTeos, Janssen, Lilly, Loxo, Mersana, Novartis, Olema Pharmaceuticals, Orum Therapeutics, Pfizer, Relay Therapeutics, Roche/Genentech, SeaGen, Stemline Therapeutics, Tubulis and Verascity Science and discloses grant/research support from Abbvie, Acerta Pharma, Accutar Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan-Florentine, Curis, CytomX, Daiichi Sankyo, Dana Farber Cancer Inst, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Ellipses Pharma, Elucida Oncology, EMD Serono, FujiFilm, G1 Therapeutics, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, InvestisBio, Jacobio, Karyopharm, K-Group Beta, Kind Pharmaceuticals, Leap Therapeutics, Lilly, Loxo Oncology, Lycera, Mabspace Biosciences, Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Novartis, Nucana, Olema, OncoMed, Onconova Therapeutics, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, SeaGen, Sermonix Pharmaceuticals, Shattuck Labs, StemCentRx, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics, Treadwell Therapeutics, Verastem, Zenith Epigenetics and Zymeworks.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed as a highlight of SABCS 2022
Access more content on Breast Cancer
Share this Video
Related Videos In Breast Cancer
Highlights in breast cancer – KEYNOTE-756, Checkmate-7FL, TOPION-Breast01, monarchE: Sara Tolaney, EMSO 2023
Significant advancements in breast cancer research emerged from EMSO this year. To highlight these key data we spoke with prominent breast medical oncologist, Dr. Sara Tolaney (Dana-Farber Cancer Institute, Boston). In this interview, Dr. Tolaney highlights some of the most valuable data including those from the KEYNOTE-756 (NCT03725059), Checkmate-7FL (NCT04109066), TOPION-Breast01 (NCT05104866) and monarchE (NCT03155997) […]
Trastuzumab duocarmazine in HER2+ metastatic breast cancer – TULIP trial results: Philippe Aftimos, ESMO 2023
The final results of the phase 3, TULIP trial (NCT03262935), which compared trastuzumab duocarmazine (T-Duo) with physician’s choice of therapy in previously treated HER2-positive metastatic breast cancer, were presented at ESMO 2023. Dr. Philippe Aftimos, the study investigator from the Institute Jules Bordet in Belgium, presented the results at the conference and then discussed them […]
Angela DeMichele, ASCO 2023: The PALLAS trial, palbociclib with adjuvant endocrine therapy in patients with stage II-III breast cancer
The PALLAS trial assessed the efficacy of adding palbociclib to adjuvant endocrine therapy in patients with stage II-III breast cancer. In this touchONCOLOGY interview, we speak with Dr Angela DeMichele (Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA) to discuss the PALLAS trial and how it compares to the other CDK4/6 inhibitor adjuvant trials, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!